DCTH logo

Delcath Systems Inc. (DCTH)

$19.37

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on DCTH

Market cap

$673844877

EPS

0.16

P/E ratio

1536

Price to sales

5.59

Dividend yield

--

Beta

0.614593

Price on DCTH

Previous close

$19.87

Today's open

$19.90

Day's range

$19.33 - $20.01

52 week range

$8.12 - $22.51

Profile about DCTH

CEO

Gerard Michel

Employees

156

Headquarters

Queensbury, NY

Exchange

NASDAQ Capital Market

Shares outstanding

34788068

Issue type

Common Stock

DCTH industries and sectors

Healthcare

Medical Equipment & Supplies

News on DCTH

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to three individuals whose grant date was in either September 2026 or October 2026. The grants, in the form of Restricted Stock Units (RSUs), totaled 21,2.

news source

Business Wire • 19 hours ago

news preview

Delcath Systems (DCTH) is on the Move, Here's Why the Trend Could be Sustainable

If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

news source

Zacks Investment Research • Nov 13, 2026

news preview

Wall Street Analysts Think Delcath Systems (DCTH) Could Surge 27.7%: Read This Before Placing a Bet

The consensus price target hints at a 27.7% upside potential for Delcath Systems (DCTH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

news source

Zacks Investment Research • Nov 12, 2026

news preview

Delcath Systems, Inc. (DCTH) is a Great Momentum Stock: Should You Buy?

Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.

news source

Zacks Investment Research • Nov 12, 2026

news preview

Delcath Systems to Be Featured on “Health Uncensored with Dr. Drew” in Segment Highlighting Advances in Liver-Directed Cancer Treatment

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the Company will be featured on Health Uncensored with Dr. Drew in a segment titled “Precision Oncology: Changing the Game for Metastatic Liver Cancer.” The segment is scheduled to air nationally on Sunday, November 15, 2026. A podcast is also expected to be released following the television broadcast.

news source

Business Wire • Nov 11, 2026

news preview

Delcath Systems Q3 Earnings Call Highlights

Delcath Systems NASDAQ: DCTH reported record third-quarter revenue of $35.1 million, up 71% from a year earlier, as use of its HEPZATO KIT increased across U.S. treatment centers. The company also raised its full-year revenue outlook and reported higher net income and positive operating cash flow.

news source

MarketBeat • Nov 9, 2026

news preview

Delcath Systems, Inc. (DCTH) Q3 2026 Earnings Call Transcript

Delcath Systems, Inc. (DCTH) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 9, 2026

news preview

Delcath Systems Reports Third Quarter 2026 Results and Business Highlights

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Results Total revenue of $35.1 million, compared with $20.6 million in the third quarter of 2025 HEPZATO KIT™ revenue of $32.7 million, compared to $19.3 million in the third quarter of 2025.

news source

Business Wire • Nov 9, 2026

news preview

Delcath Systems, Inc. (DCTH) Q3 Earnings and Revenues Top Estimates

Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to earnings of $0.02 per share a year ago.

news source

Zacks Investment Research • Nov 9, 2026

news preview

Delcath Systems: Intriguingly Poised Ahead Of Q3 Earnings

Delcath Systems, which has outperformed other Russell 2000 stocks and healthcare equipment makers by 3x and 8x this year, is due to publish Q3 results on the 9th of Nov. The probability of a topline beat looks high, while a beat over 5% could be taken well; GMs may see a sequential dip but will rebound in Q4. Recent CHOPIN phase II trial success and expansion of active treatment centers enhance DCTH's growth prospects, with 24% topline growth expected in the medium term.

news source

Seeking Alpha • Nov 4, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Delcath Systems Inc.

Open an M1 investment account to buy and sell Delcath Systems Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in DCTH on M1